NCT02221544

Brief Summary

This study is a double blind comparative study examining the effectiveness of the rTMS treatment on Freezing of Gait (FOG) phenomenon in patients with Parkinson's disease. We hypothesize that treatment using rTMS stimulation on frontal lobe areas will improve gait quality and decrease the frequency of FOG in patients with Parkinson's disease.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 20, 2014

Completed
12 days until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

August 20, 2014

Status Verified

August 1, 2014

Enrollment Period

1.2 years

First QC Date

August 19, 2014

Last Update Submit

August 19, 2014

Conditions

Keywords

Parkinson's disease, rTMS, Freezing of Gait

Outcome Measures

Primary Outcomes (1)

  • Changes in frequency and severity of the freezing of gait phenomenon

    The new version of the Freezing of Gait questionnaire will be used to quantify the frequency and severity of this symptom. The score will be compared to baseline.

    One week post intervention

Secondary Outcomes (5)

  • Community ambulation

    One week post intervention

  • Changes in endurance

    One week post intervention

  • Balance

    One week post intervention

  • Immediate changes in blood pressure

    Every session, immediately after receiving the treatment

  • Immediate change in gait function

    One week post intervention

Study Arms (2)

rTMS treatment followed by Sham

EXPERIMENTAL

A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment

Device: Low-frequency repetitive Transcranial Magnetic StimulationDevice: rTMS maintenanceDevice: ShamDevice: Sham maintenance

Sham treatment followed by rTMS

EXPERIMENTAL

A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS

Device: Low-frequency repetitive Transcranial Magnetic StimulationDevice: rTMS maintenanceDevice: ShamDevice: Sham maintenance

Interventions

Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour. The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain.

Also known as: rTMS treatment
Sham treatment followed by rTMSrTMS treatment followed by Sham

Same treatment as in rTMS treatment intervention, but only once a week for a month

Sham treatment followed by rTMSrTMS treatment followed by Sham
ShamDEVICE

Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.

Sham treatment followed by rTMSrTMS treatment followed by Sham

The same as Sham stimuli intervention, but once a week for a month

Sham treatment followed by rTMSrTMS treatment followed by Sham

Eligibility Criteria

Age50 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Idiopathic Parkinson's disease (PD), as diagnosed by a neurologist.
  • The mini-mental state examination questionnaire score above 24 points.
  • Suffer from a disabling phenomenon called Freezing of Gait (FoG) (Freezing Of Gait questionnaire score\> = 10)
  • Negative responses to the Preliminary Safety Magnetic Stimulation Treatment questionnaire.

You may not qualify if:

  • Other neurological or psychiatric disorders.
  • Severe personality disorder.
  • High Blood Pressure.
  • History of epilepsy, seizures or convulsions.
  • History of epilepsy or convulsions in first-degree relatives.
  • History of head injury or stroke.
  • Metal remains of the skull or inside the brain (outside the oral cavity).
  • Surgeries including metallic implants or known history of metal particles in the eye, pacemakers, hearing devices transplantation, or medical pumps.
  • Current history of migraines for the last six months.
  • A history of drug or alcohol abuse
  • Other medical research in the time to experiment or three months ahead. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Nir Giladi, MD

    Tel-Aviv Sourasky Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nir Giladi, MD

CONTACT

Anat Mirelman, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of the R&D division in the Tel Aviv Sourasky Medical Center (TASMC)

Study Record Dates

First Submitted

August 19, 2014

First Posted

August 20, 2014

Study Start

September 1, 2014

Primary Completion

December 1, 2015

Study Completion

December 1, 2016

Last Updated

August 20, 2014

Record last verified: 2014-08

Locations